Business Context and Reporting Period
This Form 8-K is a current report filed by NantKwest, Inc. (not Immunitybio, Inc.) on November 10, 2015. The filing discloses a change in executive leadership, specifically the appointment of a new Chief Financial Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and compensation arrangements.
Material Changes
- Executive Appointment: Angela Wilson was appointed as Chief Financial Officer, effective November 13, 2015.
- Executive Departure: Richard Gomberg, who served as CFO since January 2010 as an independent contractor, is being replaced.
- Compensation Structure: Ms. Wilson's employment agreement includes a base salary of $275,000, a target annual bonus of 45% of base salary, and 35,000 restricted stock units (RSUs).
- Severance Terms: In the event of termination without cause within 24 months, Ms. Wilson is eligible for a cash payment equal to six months of her then-current salary.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or management commentary regarding business performance. No specific risks or contingencies are disclosed in this document other than the standard reference to the full employment agreement text.
Investor Verification Checklist
- Verify the full text of the Employment Agreement for Angela Wilson, which is referenced as an exhibit to the upcoming Form 10-K.
- Confirm the vesting schedule details for the 35,000 RSUs granted to the new CFO.
- Review the transition plan for financial reporting responsibilities between the outgoing contractor and the new full-time CFO.